PIK3CG and neoplasm: In contrast, TAMs from RAS-driven mesenchymal-like tumor exhibit pro-inflammatory and pro-angiogenic signaling, resulting in resistance to PLX3397 monotherapy or combination therapy with anti-PIK3 pathway22.